Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$30B
P/E
N/A
Revenue Growth
+40.0%
Gross Margin
N/A
ROE
N/A
About Alnylam Pharmaceuticals
As a mid-cap biotech company trading on the NASDAQ, Alnylam Pharmaceuticals has established itself, with direct, concentrated exposure to the biotech and genomics theme. RNA interference therapeutics leader with approved treatments for rare diseases. With a $30B market capitalization and no current profitability, the company demonstrates exceptional revenue growth at +40% year-over-year.
Expert Coverage
Unlock Full ALNY Analysis
Expert analysis and coverage for Alnylam Pharmaceuticals
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-05-07
More in Biotech & Genomics
LLY
Eli Lilly and Company
92
True North
Mixed
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
NYSE
MCap $750BRev +32%P/E 65CRSP
CRISPR Therapeutics
89
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%BEAM
Beam Therapeutics
89
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
89
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55